The National Cancer Institute publishes the Comprehensive Cancer Control Branch
Program Evaluation Toolkit. On pages 25–29, the discussion centers on the identification and engagement of stakeholders.
https://www.cdc.gov/cancer/ncccp/pdf/CCC_Program_Evaluation_Toolkit.pdf
Write a 250- to 300-word response to the following:
What additional stakeholders might be valuable participants in the evaluation? What would they want to know?
Could this
toolkit be transitioned to other disease prevention programs? If so, would the
stakeholders be drastically different? Why or why not?
Include your own experience as
well as 2 citations that align with or contradict your comments as sourced from peer-
reviewed academic journals, industry publications, books, and/or other sources. Cite
your sources using APA formatting. If you found information that contradicts your
experience, explain why you agree or disagree with the information.
